Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

ImprimisRx Wins $34.9M Trademark Case Against OSRX

In a landmark decision, a California jury unanimously ruled in favor of ImprimisRx in its trademark infringement lawsuit against OSRX and its related entity Ocular Science, according to a press release. The jury awarded ImprimisRx a total of $34.9 million…

AOAExcel Endorses Barti Software as First Eye Care EHR

AOAExcel, a for-profit subsidiary and member-benefit arm of the American Optometric Association (AOA), has announced its first-ever endorsement of an Electronic Health Records (EHR) system—Barti Software. This partnership includes a financial investment in the San Francisco-based EHR provider, marking a…

J&J Names Shawn Millerick Vision Care President

Johnson & Johnson has announced the appointment of Shawn Millerick as the new President of Vision Care, Americas, effective November 11, 2024. In his new role, Mr. Millerick will oversee the strategy and growth of Johnson & Johnson’s Vision Care…

Avirmax Launches ABI-110 Gene Therapy Trial for Wet AMD

Avirmax Biopharma has reached a major milestone in its mission to revolutionize the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) by successfully dosing the first patient in the phase I/IIa clinical trial of ABI-110, the…

NHS Launches OCT Scans for Diabetic Eye Care

The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…

Ocular Pain in DED: Insights from the Tibetan Plateau

A recent Chinese study has shed light on the prevalence and influencing factors of ocular pain in individuals suffering from dry eye disease (DED) residing at high altitudes on the Tibetan Plateau. Co-authored by Peng-Cheng Zhang, MD, PhD, and Wen-Shan…

CHMP Endorses FYB203: Aflibercept Biosimilar Approval

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…

The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 19, a comparative study of the cost and carbon footprint of local anaesthesia techniques for cataract surgery | Eye – Nature

The Royal College of Ophthalmologists’ National Ophthalmology Database study of cataract surgery: report 19, a comparative study of the cost and carbon footprint of local anaesthesia techniques for cataract surgery | Eye  Nature Source: Author: | Date: 2024-11-23 08:00:00 Source: Author:…

Stay informed and not overwhelmed, subscribe now!